Revolution Medicines (RVMD) Net Cash Flow (2019 - 2026)

Revolution Medicines has reported Net Cash Flow for 8 years, with the latest figure at $57.2 million in Q1 2026.

• For the quarter ending Q1 2026, Net Cash Flow rose 127.3% year-over-year to $57.2 million; the trailing twelve-month figure through Mar 2026 stood at $108.5 million (up 137.05% YoY), and the FY2025 full-year result was -$158.2 million, down 3.77% from the prior year.
• Net Cash Flow for Q1 2026 stood at $57.2 million, down from $166.3 million in the prior quarter.
• The five-year high for Net Cash Flow was $342.6 million in Q4 2024, with the low at -$407.7 million in Q1 2024.
• Average Net Cash Flow over 5 years is $19.7 million, with a median of -$10.8 million recorded in 2022.
• Peak annual rise in Net Cash Flow reached 2554.39% in 2023, while the deepest fall reached 667.35% in 2023.
• Tracing RVMD's Net Cash Flow over 5 years: stood at -$17.5 million in 2022, then surged by 2030.45% to $338.4 million in 2023, then climbed by 1.25% to $342.6 million in 2024, then tumbled by 51.46% to $166.3 million in 2025, then sank by 65.61% to $57.2 million in 2026.
• The last three Net Cash Flow figures came in at $57.2 million (Q1 2026), $166.3 million (Q4 2025), and -$184.1 million (Q3 2025), per Business Quant data.

Peer Comparison